Press Release: PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna...
Press Release: PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna(TM) (ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy
About this item
Full title
Press Release: PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna(TM) (ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy
Publisher
New York: Dow Jones & Company Inc
Journal title
Dow Jones Institutional News, 2022
Language
English
Formats
Publication information
Publisher
New York: Dow Jones & Company Inc
Subjects
More information
Alternative Titles
Full title
Press Release: PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna(TM) (ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_wirefeeds_2678592092
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_2678592092
How to access this item
Log in as a Library member
